The new approval applies to both adult and pediatric patients with a narrow pulmonary Valve or severe-e**ugh pulmonary regurgitation due to congenital Heart disease.
“U.S. approval of the SAPIEN XT Valve for Pulmonic procedures provides an important, minimally invasive treatment option for a small group of patients who typically face the burden of multiple open-heart surgeries, oftentimes beginning at birth or during childhood. As risks increase with each open-heart surgery, a **n-surgical option can help them receive treatment, recover and return to **rmal activities sooner,” said Larry L. Wood, Edwards’ corporate vice president, Transcatheter Heart valves, in a statement.